Wick Capital Partners LLC Acquires Shares of 32,845 Exelixis, Inc. $EXEL

Wick Capital Partners LLC acquired a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) in the 4th quarter, HoldingsChannel.com reports. The firm acquired 32,845 shares of the biotechnology company’s stock, valued at approximately $1,440,000.

Several other hedge funds and other institutional investors also recently modified their holdings of EXEL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Exelixis by 81.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,181 shares of the biotechnology company’s stock worth $1,592,000 after purchasing an additional 19,407 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Exelixis by 4.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,466,779 shares of the biotechnology company’s stock valued at $54,153,000 after buying an additional 68,133 shares in the last quarter. Focus Partners Wealth raised its stake in Exelixis by 83.4% during the first quarter. Focus Partners Wealth now owns 38,458 shares of the biotechnology company’s stock valued at $1,420,000 after buying an additional 17,483 shares in the last quarter. Geneos Wealth Management Inc. lifted its holdings in Exelixis by 134.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 1,647 shares of the biotechnology company’s stock worth $61,000 after buying an additional 944 shares during the last quarter. Finally, Sivia Capital Partners LLC lifted its holdings in Exelixis by 23.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 14,362 shares of the biotechnology company’s stock worth $633,000 after buying an additional 2,764 shares during the last quarter. Institutional investors own 85.27% of the company’s stock.

Exelixis Stock Down 1.0%

Shares of EXEL stock opened at $51.91 on Friday. The company has a market cap of $13.05 billion, a P/E ratio of 17.25, a PEG ratio of 1.51 and a beta of 0.41. The business has a 50 day moving average of $48.66 and a two-hundred day moving average of $45.15. Exelixis, Inc. has a 52 week low of $33.76 and a 52 week high of $53.93.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.75 by $0.12. The business had revenue of $610.81 million for the quarter, compared to analysts’ expectations of $607.51 million. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.The business’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.55 EPS. Analysts expect that Exelixis, Inc. will post 3.16 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on EXEL shares. Zacks Research downgraded Exelixis from a “strong-buy” rating to a “hold” rating in a report on Thursday, March 5th. Wall Street Zen upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Exelixis in a report on Tuesday, May 19th. Wells Fargo & Company boosted their target price on shares of Exelixis from $35.00 to $40.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 6th. Finally, TD Cowen increased their target price on shares of Exelixis from $51.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $47.35.

Insider Activity

In other news, Director Maria C. Freire sold 20,634 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $46.00, for a total transaction of $949,164.00. Following the completion of the transaction, the director owned 100,819 shares of the company’s stock, valued at approximately $4,637,674. The trade was a 16.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Christopher J. Senner sold 34,901 shares of the company’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $50.00, for a total transaction of $1,745,050.00. Following the transaction, the chief financial officer owned 952,317 shares of the company’s stock, valued at $47,615,850. This represents a 3.54% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 219,170 shares of company stock worth $10,620,641 over the last 90 days. Insiders own 2.60% of the company’s stock.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.